Levin MH et al., 1983: JAMA case report of two patients on high-dose oral mebendazole for echinococcosis who developed severe reversible neutropenia. The authors estimate neutropenia may occur in up to 5% of patients on high-dose therapy.
Two patients receiving oral high-dose mebendazole therapy for echinococcosis were found to have severe, reversible neutropenia, apparently due to marrow suppression; platelets and RBCs were also reversibly suppressed in one.
Levin MH et al., 1983: JAMA case report of two patients on high-dose oral mebendazole for echinococcosis who developed severe reversible neutropenia. The authors estimate neutropenia may occur in up to 5% of patients on high-dose therapy. Case report (2 patients); United States (University of Illinois and CDC collaborators); mebendazole oral high dose, exact mg/kg not stated in the abstract, one patient with a serum level of 239 ng/mL; duration not stated. Funder: not stated. Declared conflicts: none recorded. Product: mebendazole, manufacturer not stated. Comparator: none. The 5% estimate is the authors' figure and is widely quoted; it is not a measured incidence from a cohort. Study type: case report.
